One Rock Capital Partners Acquires Innophos for $32.00 per Share (~$932M)

BioMarin Pharmaceutical Completes Acquisition of Inozyme Pharma

May 16, 2025

Healthcare Services

BioMarin Pharmaceutical Inc. completed its all-cash acquisition of Inozyme Pharma, Inc. for $4.00 per share, valuing the deal at approximately $270 million. The transaction adds INZ-701, a late-stage enzyme replacement therapy being developed for ENPP1 Deficiency, to BioMarin’s enzyme therapies portfolio.

Roquette To Acquire IFF Pharma Solutions in Up to $2.85 Billion Deal

March 20, 2024

Pharmaceuticals

IFF has entered into a definitive agreement to sell its Pharma Solutions business unit to Roquette for an enterprise value of up to $2.85 billion. The transaction is expected to close in the first half of 2025, subject to customary closing conditions and regulatory approvals.

Nordic Capital-Led Consortium Takes Inovalon Private

November 24, 2021

Healthcare Services

Inovalon, a cloud-based healthcare data platform provider, was acquired in an all-cash transaction by an equity consortium led by Nordic Capital and joined by Insight Partners, 22C Capital, and Inovalon founder and CEO Keith Dunleavy, M.D., along with certain Class B stockholders. The deal values Inovalon at an enterprise value of about $7.3 billion and provides Inovalon stockholders $41.00 per share in cash to take the company private.

Bain Capital Private Equity Takes Majority Stake in InnovaCare Health

November 19, 2021

Healthcare Services

Bain Capital Private Equity has signed a definitive agreement to acquire a majority stake in InnovaCare Health, a regional leader in integrated and value-based healthcare services. The investment will support InnovaCare's national expansion and accelerate growth of its physician-led, value-based care model; Summit Partners will remain an equity holder and management will retain significant ownership.

One Rock Capital Partners Acquires Kankakee Specialty Chemicals Site from BASF (Kensing)

June 1, 2021

Manufacturing

One Rock Capital Partners' affiliate has completed the acquisition of BASF's Kankakee, Illinois manufacturing site and associated specialty-chemicals businesses and established the standalone company Kensing. The newly independent business, led by CEO Serge Rogasik, employs roughly 160–190 people and produces plant-derived specialty ingredients (phytosterols, natural vitamin E, anionic surfactants and esters) serving personal care, food & nutrition, healthcare and agriculture markets.

Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics

August 31, 2020

Biotechnology

Ionis Pharmaceuticals agreed to acquire the approximately 24% of Akcea Therapeutics it does not already own for $18.15 per share in cash, implying a fully diluted transaction value of about $500 million. The deal will be executed via a tender offer followed by a second-step merger, and Ionis expects to complete the transaction in Q4 2020 to consolidate Akcea's pipeline, commercial products and cash while realizing cost synergies.